SG11201705952SA - Heterocyclic compound and pharmaceutical composition comprising same - Google Patents
Heterocyclic compound and pharmaceutical composition comprising sameInfo
- Publication number
- SG11201705952SA SG11201705952SA SG11201705952SA SG11201705952SA SG11201705952SA SG 11201705952S A SG11201705952S A SG 11201705952SA SG 11201705952S A SG11201705952S A SG 11201705952SA SG 11201705952S A SG11201705952S A SG 11201705952SA SG 11201705952S A SG11201705952S A SG 11201705952SA
- Authority
- SG
- Singapore
- Prior art keywords
- same
- pharmaceutical composition
- heterocyclic compound
- heterocyclic
- compound
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20150017339 | 2015-02-04 | ||
| PCT/KR2016/001133 WO2016126085A2 (en) | 2015-02-04 | 2016-02-02 | Heterocyclic compound and pharmaceutical composition comprising same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201705952SA true SG11201705952SA (en) | 2017-09-28 |
Family
ID=56564854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201705952SA SG11201705952SA (en) | 2015-02-04 | 2016-02-02 | Heterocyclic compound and pharmaceutical composition comprising same |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US10227328B2 (en) |
| EP (1) | EP3255042B1 (en) |
| JP (1) | JP6615899B2 (en) |
| KR (1) | KR101783642B1 (en) |
| CN (1) | CN107250130B (en) |
| AU (1) | AU2016216253B2 (en) |
| BR (1) | BR112017016465B1 (en) |
| CA (1) | CA2974788C (en) |
| DK (1) | DK3255042T3 (en) |
| ES (1) | ES2854707T3 (en) |
| IL (1) | IL253538B (en) |
| RU (1) | RU2710743C2 (en) |
| SG (1) | SG11201705952SA (en) |
| WO (1) | WO2016126085A2 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220130249A (en) | 2016-05-26 | 2022-09-26 | 리커리엄 아이피 홀딩스, 엘엘씨 | EGFR inhibitor compounds |
| US12391669B2 (en) * | 2018-08-30 | 2025-08-19 | The Regents of the University of California et al. | Substituted pyrimidines as IRE1 kinase inhibitors |
| AU2020215684B2 (en) * | 2019-01-29 | 2025-08-21 | Beta Pharma, Inc. | 2h-indazole derivatives as therapeutic agents for brain cancers and brain metastases |
| KR20210029693A (en) | 2019-09-06 | 2021-03-16 | 비욘드바이오주식회사 | 2,6-Bis-(2-aminopyrimidin-4-yl)pyridin-3-ol dihydrochloride and pharmaceutical composition comprising the same |
| KR102443873B1 (en) * | 2019-09-06 | 2022-09-19 | 비욘드바이오주식회사 | Method for preparing pyrimidinyl bipyridine compound and intermediate therefor |
| KR102501514B1 (en) | 2019-09-06 | 2023-02-21 | 비욘드바이오주식회사 | 2'-Amino-6-(2-amino-6-(1-isopropylpiperidin-4-yl)-5-methylpyrimidin-4-yl)-3'-fluoro-[2,4'-bipyridin]-5-ol trihydrochloride and pharmaceutical composition comprising the same |
| KR20210029694A (en) | 2019-09-06 | 2021-03-16 | 비욘드바이오주식회사 | 2'-Amino-6-(2-amino-6-methylpyrimidin-4-yl)-3'-fluoro-[2,4'-bipyridin]-5-ol dihydrochloride and pharmaceutical composition comprising the same |
| US20230019999A1 (en) * | 2019-11-18 | 2023-01-19 | Chugai Seiyaku Kabushiki Kaisha | Combination drug |
| CN111558044B (en) * | 2020-06-01 | 2022-02-11 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | Pharmaceutical composition containing sunitinib, and preparation and application thereof |
| CN116082310B (en) * | 2023-02-17 | 2024-08-20 | 厦门大学 | Bipyridine amide derivatives and their preparation and application |
| CN116751195B (en) * | 2023-06-21 | 2025-03-07 | 杭州科兴生物化工有限公司 | Bipyridine compound, pharmaceutically acceptable salt thereof, preparation method and application |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6440965B1 (en) * | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
| GB0013655D0 (en) * | 2000-06-05 | 2000-07-26 | Prolifix Ltd | Therapeutic compounds |
| KR100850728B1 (en) * | 2000-06-12 | 2008-08-06 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
| JP2004534779A (en) * | 2001-05-30 | 2004-11-18 | エルジー ライフサイエンス リミテッド | Protein kinase inhibitors for disease treatment |
| GB0129260D0 (en) * | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
| US7304071B2 (en) * | 2002-08-14 | 2007-12-04 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| CN1742723A (en) | 2004-09-02 | 2006-03-08 | 天津倍方科技发展有限公司 | Medicine composition containing temozolomide-8-carboxylic ether and use of such compound for preparing anti-tumor medicine |
| WO2008106202A1 (en) * | 2007-02-27 | 2008-09-04 | Housey Gerard M | Theramutein modulators |
| WO2010018458A2 (en) * | 2008-08-12 | 2010-02-18 | Crystalgenomics, Inc. | Phenol derivatives and methods of use thereof |
-
2016
- 2016-02-02 SG SG11201705952SA patent/SG11201705952SA/en unknown
- 2016-02-02 WO PCT/KR2016/001133 patent/WO2016126085A2/en not_active Ceased
- 2016-02-02 CN CN201680008749.8A patent/CN107250130B/en active Active
- 2016-02-02 JP JP2017541860A patent/JP6615899B2/en active Active
- 2016-02-02 BR BR112017016465-5A patent/BR112017016465B1/en active IP Right Grant
- 2016-02-02 KR KR1020160013029A patent/KR101783642B1/en active Active
- 2016-02-02 US US15/546,714 patent/US10227328B2/en active Active
- 2016-02-02 RU RU2017130825A patent/RU2710743C2/en active
- 2016-02-02 CA CA2974788A patent/CA2974788C/en active Active
- 2016-02-02 ES ES16746826T patent/ES2854707T3/en active Active
- 2016-02-02 EP EP16746826.3A patent/EP3255042B1/en active Active
- 2016-02-02 DK DK16746826.3T patent/DK3255042T3/en active
- 2016-02-02 AU AU2016216253A patent/AU2016216253B2/en active Active
-
2017
- 2017-07-18 IL IL253538A patent/IL253538B/en active IP Right Grant
-
2019
- 2019-01-07 US US16/241,177 patent/US10611754B2/en active Active
-
2020
- 2020-02-21 US US16/798,134 patent/US20200190062A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2974788C (en) | 2023-04-11 |
| NZ734084A (en) | 2023-09-29 |
| KR101783642B1 (en) | 2017-10-10 |
| US10227328B2 (en) | 2019-03-12 |
| CN107250130B (en) | 2019-11-08 |
| BR112017016465B1 (en) | 2023-11-14 |
| CA2974788A1 (en) | 2016-08-11 |
| EP3255042A4 (en) | 2018-08-01 |
| IL253538A0 (en) | 2017-09-28 |
| US20180273510A1 (en) | 2018-09-27 |
| US20200190062A1 (en) | 2020-06-18 |
| AU2016216253A1 (en) | 2017-08-17 |
| US20190135786A1 (en) | 2019-05-09 |
| JP6615899B2 (en) | 2019-12-04 |
| IL253538B (en) | 2020-09-30 |
| KR20160096033A (en) | 2016-08-12 |
| EP3255042B1 (en) | 2020-12-30 |
| AU2016216253B2 (en) | 2019-11-21 |
| RU2017130825A (en) | 2019-03-04 |
| JP2018504449A (en) | 2018-02-15 |
| CN107250130A (en) | 2017-10-13 |
| EP3255042A2 (en) | 2017-12-13 |
| DK3255042T3 (en) | 2021-02-08 |
| WO2016126085A3 (en) | 2016-11-03 |
| US10611754B2 (en) | 2020-04-07 |
| RU2710743C2 (en) | 2020-01-10 |
| WO2016126085A2 (en) | 2016-08-11 |
| RU2017130825A3 (en) | 2019-08-12 |
| BR112017016465A2 (en) | 2018-06-19 |
| ES2854707T3 (en) | 2021-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282584A (en) | Quinoline derivatives and pharmaceutical compositions containing them | |
| IL258180B (en) | Heterocyclic compounds and uses thereof | |
| IL258082B (en) | Bezimidazole derivatives and pharmaceutical compositions containing them | |
| ZA201802125B (en) | Pharmaceutical composition and application thereof | |
| IL269061A (en) | Pharmaceutical composition comprising selexipag | |
| IL271986B1 (en) | Pharmaceutical composition | |
| IL247062A0 (en) | Heterocyclic compounds , their preparation and compositions pharmaceutical containing them | |
| IL253538A0 (en) | Heterocyclic compound and pharmaceutical composition comprising same | |
| PL3287443T3 (en) | 6-membered heterocyclic derivative and pharmaceutical composition comprising same | |
| PT3202759T (en) | Alpha-aminoamide derivative compound and pharmaceutical composition comprising same | |
| GB201712159D0 (en) | Pharmaceutical composition | |
| GB201521462D0 (en) | Pharmaceutical composition | |
| HUE068810T2 (en) | Pharmaceutical composition | |
| IL263040A (en) | Pharmaceutical composition comprising eteplirsen | |
| IL272419A (en) | Pharmaceutical composition | |
| GB201719447D0 (en) | Pharmaceutical composition | |
| SG10202106375UA (en) | Pharmaceutical compositions and use thereof | |
| PL3288933T3 (en) | Oxindole compounds and pharmaceutical compositions thereof | |
| GB201515310D0 (en) | Pharmaceutical composition | |
| IL254711B (en) | Diazepino-indole derivatives and pharmaceutical compositions comprising it | |
| PL3389638T3 (en) | Pharmaceutical composition comprising pimobendan | |
| GB201520862D0 (en) | Pharmaceutical composition | |
| PL3424500T3 (en) | Pharmaceutical composition comprising famitinib | |
| GB201708328D0 (en) | Pharmaceutical composition | |
| GB201708329D0 (en) | Pharmaceutical composition |